NCT04811131 - Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo | Biotech Hunter

Enrollment

114

Participants

Timeline

Start Date

March 4, 2021

Primary Completion Date

August 9, 2021

Study Completion Date

August 9, 2021

Conditions

Vitiligo

Interventions

DRUG

ARQ-252 cream 0.3%

DRUG

ARQ-252 Vehicle cream

DEVICE

NB-UVB phototherapy active treatment

DEVICE

NB-UVB phototherapy sham treatment

Trial Locations (5)

Arcutis Site 167, Coral Gables

Arcutis Clinical Site 102, Rolling Meadows

Arcutis Clinical Site 163, Pflugerville

Arcutis Site 162, Austin

Arcutis Site 123, San Diego